MORE ARTICLES

Stay Connected!

Receive the latest updates in your inbox.

LATEST ARTICLES

Federal Firearm Forfeiture: SCOTUS Considers Gun Rights and Due Process

/in , , /by Editorial Staff

Joe Selvaggi hosts a conversation with constitutional legal expert Clark Neily, who delves into the facts and legal complexities surrounding USA v. Rahimi, currently before the Supreme Court. This case questions the forfeiture of Second Amendment rights for individuals accused of domestic abuse.

Massachusetts Residents Score a ‘D’ in Poll Based on U.S. Citizenship Test

/in , /by Editorial Staff

When asked a series of questions about how the federal government works that are based on the U.S. citizenship test, Massachusetts residents answered on average 63 percent of them correctly, earning a collective grade of “D” in a poll commissioned by Pioneer Institute and conducted by Emerson College Polling. The result is just over the 60 percent score required to pass the actual citizenship test.

Rising Dough: The Blue Frog Bakery Journey, Immigration, and Community Impact

/in , , /by Editorial Staff

Entrepreneur Brad Brown, an immigrant, shares his journey and success with Blue Frog Bakery in Jamaica Plain, highlighting community engagement and immigration’s broader impact.

Pioneer Study: Study Finds Patent Protections Fuel Biopharma Innovation that Helps Patients

/in , , /by Editorial Staff

Patent protections on new drugs have unleashed an unprecedented wave of innovation that has benefited patients and should be fiercely guarded, according to a new study published by Pioneer Institute. New research indicates that price controls contained in the Inflation Reduction Act will result in 230 fewer drugs coming to market over the next decade and job losses of between 730,000 and 1.1 million.

Ron DeSantis’ Silly Drug Importation Idea

/in , , , /by William Smith

Ron DeSantis proposed in November 2020 to import drugs from Canada for state agencies such as Medicaid, prisons and other public healthcare programs. The goal is to save $150 million in state taxpayer funds. But the Biden administration seems unlikely to approve the plan, and the FDA has raised objections. Here’s why the DeSantis plan will not — and cannot — save even a dollar.